<DOC>
	<DOC>NCT02564770</DOC>
	<brief_summary>This is a cross-sectional, observational study examining the factors leading to the therapeutic decision to use MabThera (rituximab) in participants with RA. Routine rheumatology clinical practice data of participants who are being or have been treated with rituximab for RA will be collected and analysed in this chart review.</brief_summary>
	<brief_title>A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Greater than or equal to (&gt;=) 18 years of age at the time of data collection RA diagnosed by a rheumatologist Treatment with rituximab for RA Participants whose primary diagnosis and indication for rituximab treatment is a condition other than RA Participants who have been treated with an experimental agent for RA which is not currently approved for the treatment of RA in Australia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>